Study shows skin rash in patients treated for liver cancer determines survival

	Tweet

In a study of a new chemotherapy drug for liver cancer, researchers found that the development of a skin rash correlated directly with the patient’s response to treatment.

Patients who developed a rash lived twice as long as those who did not, according to a study led by researchers at the University of Pittsburgh Cancer Institute presented at the 42nd American Society of Clinical Oncology (ASCO) Annual Meeting in Atlanta.

The study included 57 patients with advanced liver, gallbladder and bile duct cancers who were not candidates for surgery and who received a new agent called lapatinib that prevents two epidermal growth factors receptor (EGFR) pathways from becoming activated in cancer cells. The EGFR pathway has been implicated in the growth and spread of many cancers.

When the researchers evaluated the toxic effects of treatment with lapatinib, they found that twenty of the patients treated had developed a skin rash. Patients who developed the rash lived for an average of 10 months, compared to five months for those patients who did not develop a rash.

“While we don’t yet know exactly why this has been reported here and in other studies, it has implications for predicting the growth of cancer and could be a method to identify patients with advanced cancer who would be most likely to respond to this treatment,” said Ramesh K. Ramanathan, M.D., principal investigator of the study and associate professor of hematology and oncology at the University of Pittsburgh School of Medicine.

According to the study results, lapatinib was well-tolerated by the patients. Two of the patients with primary liver cancer in the study had a partial response to treatment and the disease was stabilized in an additional 17 patients.

http://www.upmc.edu/

RELATED STORIES:
Combination Therapy Improves Survival Time For Patients With Advanced Liver Cancer   Cycles of Cell Death, Proliferation Key to Liver Cancer   Liver cancer in cirrhotic patients effectively treated with radiofrequency ablation   Metformin May Protect Against Liver Cancer   Omega-3 fatty acids inhibit the growth of liver cancer cells   Wilmot Researchers Create New Way to Study Liver Cancer   Statins may cut liver cancer risk in diabetics   Liver Tumors Associated with Metabolic Syndrome Differ from Other Tumors   Studies of patients with cirrhosis uncover limitations in liver cancer screening   Researchers Find That Targeted Therapy Combination Overcomes Treatment Resistance in Liver Cancer   Type of Anesthesia May Affect Recurrence Risk after Liver Cancer Procedure   More Reliable Biomarkers Needed for Liver Cancer Detection   Research in fish provides new clues about deadly form of liver cancer   Liver transplant recipients almost 3 times more likely to develop cancer   Racial disparities evident in early-stage liver cancer survival   Hepatitis C ups liver cancer risk, study confirms   Scientists identify specific markers that trigger aggressiveness of liver cancer   Personalized treatment may help some liver cancer patients   Liver cancer patients less likely to die on wait list than candidates without carcinomas   Researchers Identify Gene Linked to Aggressive Progression of Liver Cancer   The relationship between body mass index and age at hepatocellular carcinoma onset   Proton beams control liver tumors

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]